NASDAQ$SNDX
Syndax Pharmaceuticals Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Syndax reported third quarter financial results and provided a business update.
Syndax Pharmaceuticals reported its Q3 2022 financial results, highlighting positive data from the AUGMENT-101 trial of revumenib and the completion of enrollment in the pivotal AGAVE-201 trial of axatilimab. The company is on track for two U.S. registrational filings by the end of 2023.
- Updated data from the Phase 1 portion of the AUGMENT-101 trial demonstrated a CR/CRh rate of 30% and a median durability of response of 9.1 months.
- Enrollment is complete in the pivotal Phase 2 AGAVE-201 trial of axatilimab in patients with cGVHD.
- The company remains on track for two U.S. registrational filings by the end of 2023.
- Updated positive data from the Phase 1 portion of the ongoing AUGMENT-101 trial of revumenib will be featured during two oral presentations at the American Society of Hematology (ASH) Annual Meeting in December.
Headline financials
Revenue & EPS history
Syndax · Revenue · Quarterly
$12.4M
Forward guidance
For the full year of 2022, the Company is lowering its expectations of both research and development and total operating expenses. The updated guidance reflects the benefits derived from the shared expenses for our axatilimab cGVHD development program.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+1.6%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+3.5%
Avg return
30 days after
60%
24 / 40 earnings
Positive
+15.1%
Q4 2019
Best reaction
-21.6%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.9% | -2.6% | -5.2% | |
| Q4 2025 | +5.1% | +4.6% | +13.6% | |
| Q3 2025 | +11.6% | +9.3% | +43.5% | |
| Q1 2025 | -21.6% | -21.1% | -17.8% | |
| Q4 2024 | -7.1% | -13.3% | -19.5% | |
| Q3 2024 | +12.7% | +15.2% | -11.3% | |
| Q2 2024 | -7.3% | -12.3% | -9.5% | |
| Q1 2024 | -5.2% | -9.5% | -15.9% | |
| Q4 2023 | -2.1% | -2.7% | -2.4% | |
| Q3 2023 | +6.3% | +5.0% | +19.0% | |
| Q2 2023 | -3.5% | -10.9% | -4.5% | |
| Q1 2023 | +7.8% | +5.0% | +3.8% | |
| Q4 2022 | +1.6% | -0.1% | -15.6% | |
| Q3 2022 | -2.0% | -2.2% | +9.5% | |
| Q2 2022 | +0.5% | +0.5% | -2.4% | |
| Q1 2022 | -5.8% | -12.3% | +10.1% | |
| Q4 2021 | +3.3% | -2.2% | +11.5% | |
| Q3 2021 | +2.1% | -0.9% | +5.9% | |
| Q2 2021 | +7.0% | +11.2% | +23.9% | |
| Q1 2021 | +14.6% | +18.5% | +21.5% | |
| Q4 2020 | +0.4% | -2.8% | -5.3% | |
| Q3 2020 | +8.8% | +20.4% | +30.9% | |
| Q2 2020 | +6.5% | -0.9% | +0.7% | |
| Q1 2020 | -1.8% | +3.2% | -8.0% | |
| Q4 2019 | +15.1% | +22.8% | -0.6% | |
| Q3 2019 | -0.3% | +0.3% | +24.5% | |
| Q2 2019 | +10.6% | +8.6% | -3.0% | |
| Q1 2019 | +9.1% | +6.1% | +3.9% | |
| Q4 2018 | -13.5% | -11.1% | -4.2% | |
| Q3 2018 | +2.1% | +5.9% | -3.5% | |
| Q2 2018 | +12.0% | +6.7% | +8.8% | |
| Q1 2018 | +9.9% | +1.5% | -25.5% | |
| Q4 2017 | -1.5% | -0.6% | +47.9% | |
| Q3 2017 | -11.7% | -10.1% | -28.4% | |
| Q2 2017 | -5.7% | -1.5% | +8.0% | |
| Q1 2017 | -7.0% | +4.7% | +26.7% | |
| Q4 2016 | +5.0% | +1.0% | +18.0% | |
| Q3 2016 | +0.9% | -4.9% | -17.1% | |
| Q2 2016 | +5.6% | +5.5% | +3.1% | |
| Q1 2016 | -2.1% | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro